From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

ESMO Open

Postmarketing Safety of Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Analysis of the FDA Adverse Event Reporting System (FAERS)

Journal of Thoracic Oncology

Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC

American Society of Clinical Oncology Educational Book

Biomarker Testing for Patients With Advanced Non–Small Cell Lung Cancer: Real-World Issues and Tough Choices

The ASCO Post

FDA Approves Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy for Early-Stage NSCLC

Journal of Clinical Oncology

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

Future Medicine

Diagnostic and Economic Value of Biomarker Testing for Targetable Mutations in Non-Small-Cell Lung Cancer: A Literature Review

Cancers

Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience

The ASCO Post

Julia Rotow, MD, on Patient Selection in Treating Thoracic Cancers: Looking to Driver Mutations and Biomarkers

Cancer Medicine

Defining Comprehensive Biomarker-Related Testing and Treatment Practices for Advanced Non-Small-Cell Lung Cancer: Results of a Survey of U.S. Oncologists

Journal of Clinical Oncology

Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment

Nature Reviews Clinical Oncology

Selecting the Optimal Immunotherapy Regimen in Driver-Negative Metastatic NSCLC

Cancer Cytopathology

The Rapidly Evolving Landscape of Biomarker Testing in Non–Small Cell Lung Cancer

European Journal of Cancer

RAS as a Positive Predictive Biomarker: Focus on Lung and Colorectal Cancer Patients

Journal of Clinical Oncology

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

JCO Oncology Practice

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping

Frontiers in Oncology

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review

Critical Reviews in Oncology/Hematology

Molecular Testing and Targeted Therapy for Non-Small Cell Lung Cancer: Current Status and Perspectives

Cell Reports Medicine

The Improbable Targeted Therapy: KRAS as an Emerging Target in Non-Small Cell Lung Cancer

The Oncologist

Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

The ASCO Post

Poziotinib in Previously Treated Patients With NSCLC and HER2 Exon 20 Insertion Mutations

International Journal of Molecular Sciences

The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer

Signal Transduction and Targeted Therapy

Toripalimab Plus Chemotherapy as Second-Line Treatment in Previously EGFR-TKI Treated Patients With EGFR-Mutant-Advanced NSCLC: A Multicenter Phase-II Trial

Journal of Clinical Oncology

Identifying Barriers to Equitable Biomarker Testing in Underserved Patients With NSCLC: A Mixed-Methods Study to Inform Quality Improvement Opportunities

Translational Lung Cancer Research

Emerging Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Operable Non-Small Cell Lung Cancer

JAMA Oncology

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

JCO Precision Oncology

Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

Journal of Molecular Pathology

Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer

Clinical Lung Cancer

Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists

Cancer Immunology, Immunotherapy

ZFHX3 Mutation as a Protective Biomarker for Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

Biologics: Targets and Therapy

Immunotherapeutic Advances for NSCLC

Journal of Thoracic Oncology

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Frontiers in Oncology

A Retrospective Study of Brain Metastases From Solid Malignancies: The Effect of Immune Checkpoint Inhibitors

International Association for the Study of Lung Cancer

Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer: A Mixed-Methods Survey of US-Based Oncology Clinicians

The ASCO Post

FDA Grants Accelerated Approval to Mobocertinib for Patients With Metastatic NSCLC and EGFR Exon 20 Insertion Mutations

New England Journal of Medicine

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

Cancer

Biomarkers for Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer (NSCLC)

Association of Community Cancer Centers

ACCC Principles for Drug, Diagnostics, and Biomarker Reimbursement

Journal for ImmunoTherapy of Cancer

Non-Invasive Measurement of PD-L1 Status and Prediction of Immunotherapy Response Using Deep Learning of PET/CT Images

Journal of Clinical Oncology

Journal of Thoracic Oncology

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic Non–Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort

Journal of Clinical Oncology

Biomarker Tissue Journey Among Patients With Untreated Metastatic Non–Small Cell Lung Cancer in the U.S. Oncology Network Community Practices

Dermatology

Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial

JCO Precision Oncology

MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations

Nature Reviews Clinical Oncology

Comparing and Contrasting Predictive Biomarkers for Immunotherapy and Targeted Therapy of NSCLC

The New England Journal of Medicine

Sotorasib for Lung Cancers With KRAS p.G12C Mutation

Seminars in Cancer Biology

Precision Medicine in Non-Small Cell Lung Cancer: Current Applications and Future Directions

Lung Cancer

Optimizing the Sequencing of Tyrosine Kinase Inhibitors (TKIs) in Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)

The ASCO Post

Lung Cancers With Rare EGFR Mutations Being Tackled by Novel Agents

Molecular Cancer

Management of Acquired Resistance to EGFR TKI-Targeted Therapy in Advanced Non–Small Cell Lung Cancer

Translational Lung Cancer Research

Neoadjuvant Treatment of Stage IIIA-N2 in EGFR-Mutant/ALK-Rearranged Non–Small Cell Lung Cancer

Translational Lung Cancer Research

Emerging Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Operable Non–Small Cell Lung Cancer

European Journal of Cancer

COVID-19 in Lung Cancer Patients Receiving ALK/ROS1 Inhibitors

Journal of Clinical Oncology

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Lung Cancer

Biomarker Testing in Non-Small Cell Lung Cancer in Routine Care: Analysis of the First 3,717 Patients in the German Prospective, Observational, Nation-Wide CRISP Registry (AIO-TRK-0315)

Journal of Thoracic Oncology

Biomarker Discovery and Validation: Statistical Considerations

Cancer Discovery

Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers From Admixed Latin American Populations

JCO Precision Oncology

Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer

The Lancet Oncology

Pembrolizumab for Management of Patients With NSCLC and Brain Metastases: Long-Term Results and Biomarker Analysis From a Non-Randomised, Open-Label, Phase 2 Trial

Journal of Clinical Oncology

Cardiac Safety of Osimertinib: A Review of Data

JCO Oncology Practice

Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective From the International Association for the Study of Lung Cancer Pathology Committee

Fast Facts #12: Choosing/Sequencing Therapy